Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)
CXSL1700011-III
Phase 3 mab completed
Quick answer
Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) for Norovirus Infections is a Phase 3 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Norovirus Infections
- Phase
- Phase 3
- Modality
- mab
- Status
- completed